Last reviewed · How we verify
NCT04894981: SIMADAPT2
Comparison of Power Wheelchair Driving Performance Under Immersive and Non-immersive Conditions With Drivers With Neurological Disorders
NA trial testing Immersive condition (CAVE) in Neurologic Disorder in 25 participants. Completed in 26 October 2021.
26 October 2021
Quick facts
| Lead sponsor | Pôle Saint Hélier |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 25 |
| Start date | 10 May 2021 |
| Primary completion | 26 October 2021 |
| Estimated completion | 26 October 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- Immersive condition (CAVE)
- Immersive condition (HMD)
- Non Immersive condition (Screen alone)
- Non Immersive condition (Screen with physical simulator)
Conditions studied
- Neurologic Disorder — all drugs for Neurologic Disorder →
- Brain Injuries — all drugs for Brain Injuries →
- Neurodegeneration — all drugs for Neurodegeneration →
Sponsor
Pôle Saint Hélier
Who can join
18 and older, any sex, with Neurologic Disorder or Brain Injuries. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to assess the impact of the choice of visual feedback solution (immersive via CAVE and VR headset; non-immersive via screen only) on driving performance and quality of experience on a physical driving simulator and its acceptability to wheelchair drivers with neurological disorders.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04894981
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurologic Disorder
Currently open trials in the same condition.
- NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
- NCT06208332 — The "What Is Important to Us" Communication Intervention Pilot Clinical Trial · Phase 2 · recruiting
- NCT06750692 — Comparison of the Effects of Mirror Therapy,rTMS and Robotic-assisted Hand Therapy in Stroke Patients · NA · recruiting
- NCT06883227 — Investigating Health Impacts of Exposure to Harmful Algal Blooms · recruiting
- NCT06523270 — Advanced Imaging Holistic Omics Biobank · recruiting
Other Pôle Saint Hélier trials
Trials by the same sponsor.
- NCT07230002 — Effects of Moderate/Severe Traumatic Brain Injury in the Subacute or Chronic Phase on Locomotor Strategies Involved in N · NA · recruiting
- NCT06608121 — Upper Limb Muscle Strength Models for Patients With Motor Impairment. · NA · completed
- NCT06466590 — Reliability and Validity of the French Version of the Virtual Reality Sickness Questionnaire · NA · completed
- NCT06239012 — Reliability and Validity Evaluation of the BePoW Device · NA · completed
- NCT05547295 — Evaluation of the Impact of a Digital Tool MEDIASCREEN of Preventive Information for Patients on the Knowledge of the Ri · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04894981 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pôle Saint Hélier
- Last refreshed: 1 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04894981.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing